Media stories about Mesoblast (NASDAQ:MESO) have trended somewhat positive this week, Accern Sentiment reports. The research firm identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Mesoblast earned a coverage optimism score of 0.10 on Accern’s scale. Accern also assigned media stories about the company an impact score of 45.8469833843859 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment’s rankings:
Shares of NASDAQ:MESO traded up $0.04 on Friday, reaching $5.67. The company had a trading volume of 31,880 shares, compared to its average volume of 46,786. Mesoblast has a twelve month low of $4.74 and a twelve month high of $12.50. The stock has a market capitalization of $530.18, a P/E ratio of -5.85 and a beta of 1.95.
Mesoblast (NASDAQ:MESO) last announced its quarterly earnings results on Tuesday, February 27th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.09. Mesoblast had a negative return on equity of 9.78% and a negative net margin of 188.83%. The company had revenue of $13.40 million during the quarter, compared to analysts’ expectations of $0.34 million. equities analysts forecast that Mesoblast will post -0.49 earnings per share for the current fiscal year.
MESO has been the subject of a number of analyst reports. Maxim Group set a $14.00 price target on Mesoblast and gave the stock a “buy” rating in a research report on Monday, December 18th. Zacks Investment Research raised Mesoblast from a “hold” rating to a “buy” rating and set a $6.25 price target for the company in a research report on Saturday, January 13th. Cantor Fitzgerald set a $23.00 price target on Mesoblast and gave the stock a “buy” rating in a research report on Wednesday, February 21st. Oppenheimer set a $16.00 price target on Mesoblast and gave the stock a “buy” rating in a research report on Wednesday, December 20th. Finally, Credit Suisse Group cut Mesoblast from a “neutral” rating to an “underperform” rating and set a $6.00 price target for the company. in a research report on Thursday, March 22nd. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $13.54.
TRADEMARK VIOLATION NOTICE: This news story was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dispatchtribunal.com/2018/04/07/mesoblast-meso-getting-somewhat-positive-news-coverage-analysis-shows.html.
Mesoblast Company Profile
Mesoblast Limited develops cell-based medicines. The company has leveraged its proprietary technology platform based on mesenchymal lineage adult stem cells to establish a portfolio of late-stage product candidates. Its allogeneic cell product candidates target advanced stages of diseases with high and unmet medical needs, including cardiovascular conditions, immunologic and inflammatory conditions, orthopedic disorders, and oncology and hematology conditions.
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.